Edit
Early Development Services
https://pharma.lonza.com/offerings/early-development-servicesLast activity: 21.03.2022
Active
In silico / in vitro services for manufacturability, immunogenicity, humanization, protein engineering and non-GMP protein production
Mentions in press and media 14
| Date | Title | Description |
| 21.03.2022 | After acquisitions and new deals, Recro rebrands to Societal CDMO | The team at Recro, a CDMO based out of Pennsylvania, has made a flurry of moves in the past year, expanding its operations to the West Coast with the acquisition of Irisys, and expanding its dosage forms in the process. Next up: a rebrand. ... |
| 21.03.2022 | Covid vaccine patent landscape heats up as Pfizer's partner sues Arbutus and Genevant | Just a month before Klick Health’s 25th anniversary, the pharma and healthcare agency is boosting its executive roster with a fitting 25 hires and promotions. It’s also debuting a new practice formalizing its corporate reputation business a... |
| 21.03.2022 | Lonza inks deal with first customer at recently-expanded China manufacturing site | Just one week after Swiss drugmaker Lonza announced that an expansion of its API development and manufacturing labs at a Nansha, China, site has been completed, the first partner to benefit from that upgrade has been announced. Oasmia Pharm... |
| 21.03.2022 | Covid vaccine patent landscape heats up as Pfizer's partner sues Arbutus and Genevant | The ongoing pandemic has only exacerbated racial and gender pay gaps across the board, according to Arjuna Capital and Proxy Impact’s latest scorecard. And while biopharma darling Pfizer has scored itself an A on the pay equity front, it lo... |
| 21.03.2022 | Covid vaccine patent landscape heats up as Pfizer's partner sues Arbutus and Genevant | AbbVie’s first TV commercial for Vuity eye drops for age-related vision loss stops surprised people in their tracks. “Wait, what?” the middle-aged, eyeglass-wearing actors say when they hear about the eye drops that could help them see with... |
| 21.03.2022 | Covid vaccine patent landscape heats up as Pfizer's partner sues Arbutus and Genevant | The patent landscape around the two top Covid-19 vaccines is getting more complex and contested by the day. Most recently, Canadian biotech Acuitas sued Arbutus and Genevant, two companies that Acuitas believes are making baseless claims ab... |
| 21.03.2022 | Covid vaccine patent landscape heats up as Pfizer's partner sues Arbutus and Genevant | Having settled patent lawsuits with Merck and Roche over their PD-(L)1 drugs, Bristol Myers Squibb has found a new target in its crusade to protect — and recoup any damages to — the Opdivo franchise. In a newly filed complaint, Bristol Myer... |
| 10.03.2022 | Lonza completes China expansion to support HPAPI production | At the end of 2021, a report from CPhI named Lonza among the CDMO big dogs that will soon be responsible for more than half of the world’s manufacturing capacity by 2025. The Swiss company took another step in that direction Tuesday with th... |
| 18.01.2022 | Lonza : Launches bYlok Technology for the Discovery and Design of Bispecific Antibodies | Lonza launches bYlok™ Technology - a new design engineering approach for bispecific antibodies that can streamline future clinical manufacturing The platform contributes to solving the light-heavy chain mispairing challenge with an accuracy... |
| 08.12.2021 | Lonza : Doer Biologics signs licensing agreement with Lonza to develop multi-specific biotherapeutics using XS Pichia | Doer Biologics is utilizing its proprietary MultipleBody® and SMART-VHHBody technology platforms for developing multi-specific biotherapeutics to address unmet medical needs The license agreement will leverage Lonza's XS®Pichia Expression S... |
Show more